Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Jazz-$1.1B

More Like This

PR Newswire associated0

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026

PR Newswire associated0

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire associated0

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire associated0

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

PR Newswire associated0

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024